Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 99
Updated:3/9/2019
Start Date:December 19, 2018
End Date:April 21, 2023
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

The purpose of this study is to compare the clinical activity of durvalumab alone vs
durvalumab in combination with novel agents. The overall study goal is early identification
of novel durvalumab combinations that are more active than durvalumab alone in the treatment
of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug
platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in
combination with novel agents in subjects with locally advanced, unresectable, Stage III
non-small cell lung cancer (NSCLC).

Main Inclusion Criteria:

1. Written informed consent and any locally required authorization obtained from the
subject prior to performing any protocol-related procedures, including screening
evaluation

2. Age 18 years or older

3. Body weight ≥ 35 kg

4. Subjects must have histologically or cytologically documented NSCLC who present with
locally advanced, unresectable, Stage III disease

5. Subjects must have completed, without progressing, definitive cCRT within 28 days
prior to being randomized into the study:

6. Provision of tumor tissue sample, when available, from original diagnosis obtained
before initiation of chemoradiotherapy

7. Life expectancy ≥ 12 weeks

8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

9. Subjects must have at least one previously irradiated tumor lesion that can be
measured by RECIST v1.1

Main Exclusion Criteria:

1. Mixed small cell and non-small cell lung cancer histology

2. Current or prior use of immunosuppressive medication within 14 days before the first
dose of study drug.

3. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy

4. Subjects with a history of venous thrombosis within the past 3 months

5. Subjects with history of myocardial infarction, transient ischemic attack, or stroke
in the past 6 months

6. Congestive heart failure

7. Active or prior documented autoimmune or inflammatory disorders

8. History of active primary immunodeficiency

9. Active infection including tuberculosis, hepatitis B, hepatitis C, or human
immunodeficiency virus (HIV)

10. History of allogenic organ transplantation

11. QTcF interval ≥ 470 ms

12. History of another primary malignancy

13. Concurrent enrollment in another therapeutic clinical study or during the follow-up
period of an interventional study. Enrollment in observational studies will be allowed

14. Females who are pregnant, lactating, or intend to become pregnant during their
participation in the study
We found this trial at
39
sites
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Edmonton,
Click here to add this to my saved trials
?
mi
from
Fresno, CA
Click here to add this to my saved trials
?
mi
from
Gettysburg, PA
Click here to add this to my saved trials
?
mi
from
Hammond, LA
Click here to add this to my saved trials
?
mi
from
Hinsdale, IL
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Lancaster, PA
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Richmond, VA
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Tyler, TX
Click here to add this to my saved trials
?
mi
from
Vallejo, CA
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
?
mi
from
West Haven, CT
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials
?
mi
from
Winter Haven, FL
Click here to add this to my saved trials